Physician and Patient Safety Act
Summary
The Physician and Patient Safety Act (HR3413) is an early-stage bill that mandates due process procedures for physicians before hospitals can restrict staff privileges. The bill contains no direct funding, is referred to committee with only 6 cosponsors, and carries negligible near-term market impact for the healthcare sector.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR3413 is pure regulatory mandate with zero funding — no direct money trail for investors to follow.
- 2.Bill has not moved past committee referral in 11 months; companion bill also stalled in Senate.
- 3.If enacted, hospital operators ($HCA, $UHS) face minor administrative cost friction, but impact is immaterial to earnings.
- 4.No listed physician or healthcare services company has material revenue exposure to this procedural change.
Market Implications
No actionable market implications. This bill does not alter reimbursement rates, coverage mandates, drug pricing, or any revenue driver for publicly traded healthcare companies. Hospital operators $HCA and $UHS would face negligible incremental compliance costs. Investors should monitor for unexpected movement (committee markup, inclusion in must-pass health legislation) but current baseline expectation is that HR3413 dies in committee.
Full Analysis
-
What happened: HR3413 was introduced in the House on May 14, 2025 by Rep. Ruiz (D-CA) and referred to the House Committee on Energy and Commerce. The bill has 6 cosponsors and an identical companion bill (S1767) in the Senate. As of today (April 30, 2026), the bill remains in committee with no further action — it is stalled in early stage.
-
The money trail: There is zero funding authorization or appropriation in this bill. It is a pure regulatory mandate — it instructs HHS to issue regulations requiring hospitals to provide fair hearings and appellate review before terminating or restricting physician staff privileges. No federal dollars flow. No tax credits, grants, or procurement programs are created.
-
Structural winners and losers: This is not a market-moving bill. Hospitals ($HCA, $UHS) face modest operational friction from additional administrative and legal procedures, but the cost is immaterial relative to their revenue bases (HCA's 2025 revenue ~$70B; UHS ~$16B). Physician staffing companies ($AMN, $CHG Healthcare private) could see minor benefits if the due-process protections make hospital employment less desirable, but this is speculative and not grounded in bill text. No clear winners.
-
Timeline: The bill requires HHS to issue final regulations within 18 months of enactment. However, the bill has not advanced out of committee in nearly a year. Without substantial committee leadership sponsorship or a broader legislative vehicle, passage in this Congress is unlikely.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Regulatory mandate requiring hospitals to provide fair hearing and appellate review before restricting physician staff privileges
Who must act
Hospitals that have granted medical staff privileges to physicians, including HCA Healthcare facilities
What happens
Operational cost increase from establishing and administering hearing/appellate review processes; potential delay in removing underperforming physicians from staff
Stock impact
HCA operates ~180 hospitals and ~2,300 care sites; each facility must now institute due-process hearings before restricting physician privileges, adding legal and administrative overhead. No direct revenue impact, but increased operational friction.
What the bill does
Regulatory mandate requiring hospitals to provide fair hearing and appellate review before restricting physician staff privileges
Who must act
Hospitals that have granted medical staff privileges to physicians, including Universal Health Services facilities
What happens
Operational cost increase from establishing and administering hearing/appellate review processes; potential delay in removing underperforming physicians from staff
Stock impact
UHS operates ~330 acute care hospitals and behavioral health facilities; each must implement due-process procedures before restricting privileges. Increased legal and administrative costs, no revenue impact.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
CAPEX & D SQUARE, A JOINT VENTURE LLC: $23.2M Department of Veterans Affairs Contract
Veterans’ Assuring Critical Care Expansions to Support Servicemembers (ACCESS) Act of 2025
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt".
SPREZZATURA MANAGEMENT CONSULTING, LLC: $23.2M Department of Veterans Affairs Contract
Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act of 2025
To amend title XVIII of the Social Security Act to prevent hospitals or skilled nursing facilities that are owned by certain firms from participating in the Medicare program.
CHOICE for Veterans Act of 2025
Hospital Transparency Compliance Enforcement Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.